Recovery & Tissue Repair
Peptides used for musculoskeletal healing, tissue regeneration, and injury recovery.
Clinical Overview
Recovery & Tissue Repair
Peptides used for musculoskeletal healing, tissue regeneration, and injury recovery.
Recovery and tissue-repair peptides are among the most frequently requested compounded agents in integrative, sports-medicine, and regenerative practices. Evidence remains predominantly preclinical with growing human case-series data.
Mechanism Classes
Cytoprotective / cell-signaling peptides
BPC-157 is a pentadecapeptide derived from a gastric protective protein, studied for tendon, ligament, muscle, bone, and GI healing.
Angiogenic / tissue-migration peptides
TB-500 (related to thymosin beta-4) promotes angiogenesis, cell migration, and wound healing through actin regulation.
Copper-binding tripeptides
GHK-Cu modulates skin remodeling, wound healing, and tissue antioxidant systems; used in cutaneous, wound, and scar-remodeling indications.
Growth-factor analogs
IGF-1 LR3 is a long-acting insulin-like growth factor analog with pro-anabolic effects on muscle and recovery.
Regulatory Status
FDA-Approved
None FDA-approved in this category.
Investigational / Off-Label
- BPC-157
- TB-500
- GHK-Cu
- IGF-1 LR3
None FDA-approved for recovery indications. All are compounded or research-chemical sourced. BPC-157 is FDA-classified Category 2 — compounding eligibility is contested.
Evidence Base
Extensive preclinical data across rodent and rabbit models. Limited published human data: small case series and pilot studies; no completed randomized controlled trials as of 2025.
Primary-Literature References
42
Across 3 linked monographs
Prescribing Considerations
- 1Frame as investigational and document informed consent accordingly.
- 2Source from 503A / 503B pharmacies with lot-specific Certificates of Analysis (identity, purity, endotoxin).
- 3Route selection: subcutaneous most common; intra-articular is used for joint indications — attention to sterility.
- 4Cycle duration typically 4–12 weeks; long-term continuous use has no human safety data.
- 5Active or recent malignancy is a contraindication (theoretical concern about angiogenesis / cell proliferation).
- 6Screen WADA-competing athletes — several peptides in this class are on the WADA prohibited list.
Peptides in this category(3)
Clinical monographs for each agent — dosing ranges, safety profile, evidence, and prescribing considerations.
1 additional monograph in this category is in clinical review and will be published soon.